Celgene reports Q4 adj. EPS $2.39, consensus $2.32 Reports Q4 revenue $4.04B, consensus $. “2018 was another year of excellent operating results and significant progress advancing our innovative early-, mid- and late-stage pipeline,” said Mark Alles, Chairman and CEO of Celgene (CELG). “With five near-term product launches and many promising assets advancing, we are very optimistic about our potential for long-term growth as part of the new Bristol-Myers Squibb (BMY).”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.